COM.TO - CARDIOME PHARMA CORP

Toronto - Toronto Delayed Price. Currency in CAD
2.95
-0.08 (-2.64%)
At close: 3:22PM EDT
Stock chart is not supported by your current browser
Previous Close3.03
Open3.03
Bid2.95 x 0
Ask3.09 x 0
Day's Range2.93 - 3.13
52 Week Range2.93 - 3.13
Volume9,199
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group2 months ago

    Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV

    Nasdaq: CORV TSX: CORV VANCOUVER , May 17, 2018 /CNW/ - Correvio Pharma Corp. (Nasdaq:CORV / TSX:CORV), formerly Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on ...

  • ACCESSWIRE2 months ago

    Canadian Exchanges Stock Scanner Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics Biotech

    LONDON, UK / ACCESSWIRE / May 17, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics Biotech. The TSX Venture Exchange gained 0.47 points, or 0.06%, to finish at 781.50. Today's stocks of interest consist of: Concordia International Corporation (TSX: CXR), ProMetic Life Sciences Inc. (TSX: PLI), Cardiome Pharma Corporation (TSX: COM), and Oncolytics Biotech Inc. (TSX: ONC).

  • CNW Group2 months ago

    Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China

    VANCOUVER, May 17, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CRME / TSX: COM), formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess® versus placebo in patients with recent onset atrial fibrillation (AF).  Approximately 240 patients are expected to be enrolled at an estimated 30 clinical trial sites in China. The primary objective of the study is to demonstrate the effectiveness of Brinavess in the conversion of recent onset AF to sinus rhythm, compared to placebo. Secondary objectives include assessment of the safety and tolerability of Brinavess, time to conversion of AF to sinus rhythm and pharmacokinetics, among others.

  • CNW Group2 months ago

    Correvio Reports First Quarter 2018 Financial Results

    Management to Host Conference Call and Webcast Today, May 15, 2018 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) NASDAQ: CRME  TSX: COM VANCOUVER , May 15, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CRME ...

  • CNW Group2 months ago

    Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

    VANCOUVER, May 15, 2018 /CNW/ - Correvio Pharma Corp. ("Correvio"), formerly Cardiome Pharma Corp. ("Cardiome") (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has completed its previously announced strategic transaction with Cipher Pharmaceuticals Inc. ("Cipher") (TSX:CPH.TO - News) whereby Cipher has acquired Correvio's Canadian business portfolio, including the Canadian rights to Brinavess®, Aggrastat®, Xydalba™ and Trevyent®, effective today. Cardiome has undergone a corporate restructuring by way of a statutory plan of arrangement (the "Arrangement").  Pursuant to the Arrangement, all of the outstanding common shares of Cardiome have been assigned and transferred to Cardiome's newly created wholly-owned subsidiary, Correvio Pharma Corp., in exchange for common shares of Correvio.  Each former shareholder of Cardiome now holds the same pro rata interest in Correvio as it held in Cardiome immediately prior to completion of the Arrangement.  Correvio has acquired and will hold all of Cardiome's pre-transaction assets, other than the Canadian business portfolio acquired by Cipher under the Arrangement.  Cipher has acquired all of the outstanding common shares of Cardiome, which holds only the transferred Canadian business.

  • CNW Group2 months ago

    Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call

    Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome Company to Host First Quarter 2018 Financial Results Conference Call on Tuesday, May 15, 2018 at 4:30 p.m. ET NASDAQ: ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Titan Medical, ProMIS Neurosciences, Cardiome Pharma and Valeant Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group3 months ago

    Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

    NASDAQ:CRME, TSX:COM VANCOUVER , April 26, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, ...

  • CNW Group3 months ago

    Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

    NASDAQ: CRME   TSX: COM VANCOUVER , April 17, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today ...

  • ACCESSWIRE3 months ago

    Toronto Exchanges Stock Review Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics Biotech

    LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International, ProMetic ...

  • CNW Group3 months ago

    Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018

    NASDAQ: CRME   TSX: COM Company Will Also Host Xydalba Expert Educational Session Featuring Key Opinion Leaders in the Field of Hospital Anti-Infectives VANCOUVER , April 12, 2018 /CNW/ - Cardiome Pharma ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Aphria, Titan Medical, ProMIS Neurosciences and Cardiome Pharma

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

    VANCOUVER, April 6, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") today announced that it has entered into a first amending agreement to its amended and restated term loan agreement with CRG Servicing LLC ("CRG") managed funds dated May 11, 2017 (the "Amending Agreement") to provide for certain adjustments to the financial covenants with respect to minimum revenue. Under the terms of the amended agreement, CRG has waived its right to receive payment of certain cash compensation of up to $6 million dollars that would have been required under the original agreement and has agreed to permit the divestiture of Cardiome's Canadian business portfolio under the proposed transaction with Cipher Pharmaceuticals.

  • CNW Group4 months ago

    Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission

    NASDAQ: CRME  TSX: COM VANCOUVER , April 2, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, ...

  • PR Newswire4 months ago

    Cardiome Announces Recent Insider Purchases

    NASDAQ:CRME  TSX:COM VANCOUVER , March 28, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter , President and CEO and Justin Renz , Chief Financial Officer, ...

  • CNW Group4 months ago

    Cardiome Announces Recent Insider Purchases

    NASDAQ:CRME  TSX:COM VANCOUVER , March 28, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter , President and CEO and Justin Renz , Chief Financial Officer, ...

  • PR Newswire4 months ago

    Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

    VANCOUVER, March 22, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, announced today that Health Canada has accepted its New Drug Submission (NDS) for review of Xydalba™ (dalbavancin hydrochloride) and granted Priority Review status to the application. Cardiome expects to receive an approval decision for Xydalba during the third quarter of 2018. Under the proposed strategic transaction between Cardiome and Cipher Pharmaceuticals Inc. announced earlier this week, upon the close of the transaction, Cipher would sublicense the commercial rights to Xydalba as part of the Canadian business portfolio proposed for acquisition. "Health Canada's acknowledgement regarding the completeness of the NDS submission for Xydalba and granting of Priority Review are important milestones for Cardiome," said Kiran Bhirangi, M.D., Vice President, Clinical Development and Medical Affairs.

  • CNW Group4 months ago

    Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

    Approval Decision Expected in Third Quarter 2018 NASDAQ:CRME TSX:COM VANCOUVER , March 22, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company ...

  • PR Newswire4 months ago

    Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

    MISSISSAUGA, ON, and VANCOUVER, March 20, 2018 /PRNewswire/ - Cipher Pharmaceuticals Inc. (CPH.TO) and Cardiome Pharma Corp. (Nasdaq:CRME and TSX:COM), today announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.  The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement under the Canada Business Corporations Act.  Pursuant to the arrangement, Cardiome shareholders will receive common shares, on a one-for-one ratio, of a newly created Canadian entity named Correvio Pharma Corp. that will apply for a substitution listing on the Nasdaq and TSX. Correvio will acquire and hold all of Cardiome's pre-transaction assets, excluding the Canadian business portfolio being acquired by Cipher under the arrangement.  The arrangement is described in further detail below.

  • CNW Group4 months ago

    Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

    MISSISSAUGA, ON, and VANCOUVER, March 20, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH.TO - News) and Cardiome Pharma Corp. (Nasdaq:CRME and TSX:COM), today announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.  The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement under the Canada Business Corporations Act.  Pursuant to the arrangement, Cardiome shareholders will receive common shares, on a one-for-one ratio, of a newly created Canadian entity named Correvio Pharma Corp. that will apply for a substitution listing on the Nasdaq and TSX. Correvio will acquire and hold all of Cardiome's pre-transaction assets, excluding the Canadian business portfolio being acquired by Cipher under the arrangement.  The arrangement is described in further detail below.

  • CNW Group4 months ago

    Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

    VANCOUVER, March 13, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans. Aspen Medical, who also markets Aggrastat in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.

  • PR Newswire4 months ago

    Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

    VANCOUVER, March 13, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans. Aspen Medical, who also markets Aggrastat in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.

  • ACCESSWIRE4 months ago

    Toronto Exchanges Stock Review Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics Biotech

    LONDON, UK / ACCESSWIRE / March 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International, ProMetic ...

  • CNW Group5 months ago

    Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

    NASDAQ:CRME TSX:COM VANCOUVER , March 6, 2018 /CNW/ -   Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • PR Newswire5 months ago

    Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

    NASDAQ:CRME TSX:COM VANCOUVER , March 6, 2018 /PRNewswire/ -   Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...